ENTITY
WuXi XDC

WuXi XDC (2268 HK)

179
Analysis
Industrials • China
WuXi XDC is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates. The company offers integrated, end-to-end services for the discovery, process development, and GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and payload-linkers. WuXi XDC was founded in 2013 and is headquartered in Wuxi, China.
more
bullish•Hansoh Pharmaceutical
•19 Aug 2025 19:04

Hansoh Pharma Placement - Somewhat Expected but Still Opportunistic

Hansoh Pharmaceutical Group (3692 HK) aims to raise around US$500m via a primary placement. In this note, we talk about the deal dynamics.

Logo
713 Views
Share
bullish•Pop Mart
•19 Aug 2025 13:46

Quiddity Leaderboard Hang Seng Index Sep25: BeOne, TME, and Pop Mart Among Our Top Picks

The official index change results for the Hang Seng index Sep25 review will be announced publicly on Friday (after market close). This might be a...

Logo
1.1k Views
Share
bullish•Quantitative Analysis
•10 Aug 2025 10:05

HK Connect Flows Weekly (Aug 8th): Tencent, Kuaishou, Alibaba, Meituan, Li Auto, China Mobile

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent, Kuaishou, Alibaba, Meituan, Li Auto, China Mobile.

Logo
644 Views
Share
bullish•Meituan
•04 Aug 2025 08:08

ECM Weekly (4 August 2025)-Meituan, LG CNS, Wuxi AppTec, SICC, NSDL, Aditya Info, GigaDevice, WeWork

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
917 Views
Share
bullish•WuXi AppTec
•30 Jul 2025 08:55

WuXi AppTec (2359.HK/603259.CH) 25H1 - The Turning Point of Performance Has Been Confirmed

​WuXi AppTec sees performance reversal driven by growth in TIDES/disposal of XDC shares. “Valuation discount” is inevitable to reflect geopolitical...

Logo
605 Views
Share
x